177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, Philippe B Ruszniewski, Lisa Bodei, Andrew Hendifar, Erik Mittra, Edward M Wolin, James C Yao, Marianne E Pavel, Enrique Grande, Eric Van Cutsem, Ettore Seregni, Hugo Duarte, Germo Gericke, Amy Bartalotta, Maurizio F Mariani, Arnaud Demange, Sakir Mutevelic, Eric P Krenning
Topics & Concepts
MedicineOctreotideInternal medicineOverall survivalMidgutNeuroendocrine tumorsGastroenterologyClinical trialOncologySomatostatin AnaloguePhases of clinical researchCarcinoid syndromeSurvival analysisSurgerySurvival rateResectionChemotherapyProgression-free survivalPhase (matter)PathologyComplicationUrologyNeuroendocrine Tumor Research AdvancesThyroid Cancer Diagnosis and TreatmentAdrenal and Paraganglionic Tumors